MiR-1266 suppresses the growth and metastasis of prostate cancer via targeting PRMT5
C.-M. Sun, G.-M. Zhang, H.-N. Qian, S.-J. Cheng, M. Wang, M. Liu, D. Li Department of Anesthesiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
The article “MiR-1266 suppresses the growth and metastasis of prostate cancer via targeting PRMT5, by C.-M. Sun, G.-M. Zhang, H.-N. Qian, S.-J. Cheng, M. Wang, M. Liu, D. Li, published in Eur Rev Med Pharmacol Sci 2019; 23 (15): 6436-6444–PMID: 31378882” has been withdrawn from the authors due to some inaccuracies (some data cannot be repeated by our further research).
The Publisher apologizes for any inconvenience this may cause.
Free PDF DownloadMiR-1266 suppresses the growth and metastasis of prostate cancer via targeting PRMT5

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
C.-M. Sun, G.-M. Zhang, H.-N. Qian, S.-J. Cheng, M. Wang, M. Liu, D. Li
MiR-1266 suppresses the growth and metastasis of prostate cancer via targeting PRMT5
Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 13
Pages: 4439-4439
DOI: 10.26355/eurrev_202107_26223
Publication History
Published online: 15 Jul 2021